Australien - Englisch - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

alvogen inc. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 50 mg in 50 ml - cisplatin injection is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existing renal i

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

fresenius kabi usa, llc - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - cisplatin injection is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures.  an established combination consists of cisplatin and cyclophosphamide.  cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existing renal

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

athenex pharmaceutical division, llc. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - cisplatin injection is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existing renal i

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

wg critical care, llc - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - cisplatin injection is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin injection and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with preexistin

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

gland pharma limited - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - cisplatin injection is indicated as therapy to be employed as follows: metastatic testicular tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. metastatic ovarian tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. advanced bladder cancer cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatmen

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cisplatin 1 mg/ml - solution for injection - 1 mg/ml - active: cisplatin 1 mg/ml excipient: hydrochloric acid sodium chloride water for injection - cisplatin ebewe is indicated as palliative therapy to be employed as follows: metastatic non-seminomatous germ cell carcinoma: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic non-seminomatous germ cell tumours who have already received appropriate surgical and/or radiotherapeutic procedures. metastatic ovarian tumours: cisplatin ebewe, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy who have not previously received cisplatin ebewe therapy. advanced and refractory carcinoma of the bladder: cisplatin ebewe, as a single agent, is indicated as secondary therapy in patients with advanced stage bladder cancer refractory to standard chemotherapy who have not previously received cisplatin ebewe therapy. squamous cell carcinoma of the head and neck (refractory to standard chemotherapy): cisplatin ebewe, as a single agent, is indicated as secondary therapy in patients with squamous cell carcinoma of the head and neck refractory to standard chemotherapy who have not previously received cisplatin ebewe therapy.